Equities

NuCana PLC

NuCana PLC

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)1.60
  • Today's Change0.000 / 0.03%
  • Shares traded88.55k
  • 1 Year change-84.00%
  • Beta1.0043
Data delayed at least 15 minutes, as of Nov 13 2024 19:19 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

NuCana plc is a United Kingdom-based clinical-stage biopharmaceutical company. The Company is focused on developing treatment outcomes for patients with cancer by applying its ProTide technology. The Company's pipeline includes NUC-3373, and NUC-7738. NUC-3373 is a ProTide transformation of the active anti-cancer metabolite of 5-fluorouracil (5-FU). 5-FU is a prescribed anti-cancer agent. NUC-3373 has been evaluated in a Phase I clinical trial for patients with advanced solid tumors and is under Phase Ib/II clinical trial for patients with advanced colorectal cancer. NUC-7738 is a ProTide transformation of a nucleoside analog, 3’-deoxyadenosine (3’-Da). The Company is evaluating NUC-7738 in a Phase I/II clinical trial for patients with advanced solid tumors. Its pipeline also includes Acelari, which is a ProTide transformation of the nucleoside analog gemcitabine. The Company’s subsidiaries include NuCana, Inc., NuCana Limited and NuCana BioMed Trustee Company Limited.

  • Revenue in USD (TTM)0.00
  • Net income in USD-35.93m
  • Incorporated1997
  • Employees25.00
  • Location
    NuCana PLCLochside House, 3 Lochside WayEDINBURGH EH12 9DTUnited KingdomGBR
  • Phone+44 131 248 3660
  • Fax+44 131 248 3001
  • Websitehttps://www.nucana.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Helix BioMedix, Inc.2.07m-2.58m3.45m8.00--2.21--1.67-15.60-15.6012.486.950.80471.874.55258,238.80-100.64-146.31-120.73-173.5768.9630.80-125.06-527.121.69-14.570.00--122.0792.8067.73---29.08--
Pasithea Therapeutics Corp0.00-16.37m3.51m8.00--0.2169-----14.98-14.990.0015.490.00----0.00-58.66---62.74--------------0.00-------32.23------
CTT Pharmaceutical Holdings Inc0.00-1.67m3.54m0.00--1.91-----0.0822-0.08220.000.03460.00-------317.2813.49-448.83304.48------------0.00-------3,454.52------
Gritstone bio Inc14.61m-133.03m3.54m231.00--0.1593--0.2425-1.35-1.350.13910.18840.08--49.2063,251.08-72.86-48.08-83.37-55.18-----910.50-573.71---97.110.6461---18.0568.96-15.71---4.19--
Lipella Pharmaceuticals Inc507.20k-4.14m3.57m5.00--1.65--7.03-4.95-4.950.59191.790.1788--16.01101,440.00-146.02---169.27-------816.72------0.00--144.15---77.81------
TNF Pharmaceuticals Inc0.00-7.07m3.57m9.00--0.1321-----5.53-5.530.0010.280.00----0.00-25.59-76.20-31.13-84.38--7.64---4,290.96----0.00------49.15------
Protagenic Therapeutics Inc0.00-6.40m3.57m1.00--4.51-----1.45-1.450.000.17740.00----0.00-152.72-74.49-206.36-92.56-----------17.090.00-------40.64------
Oncternal Therapeutics Inc1.85m-35.97m3.58m27.00--0.2274--1.94-12.19-12.190.62545.320.0495----68,370.37-96.40-49.40-116.52-54.51-----1,948.70-1,342.98----0.00---47.32--10.62------
Hepion Pharmaceuticals Inc0.00-28.37m3.62m22.00--1.94-----6.49-6.490.000.61420.00----0.00-133.45-61.43-167.53-68.82------------0.00-------7.92------
NuCana PLC (ADR)0.00-35.93m3.63m25.00--0.7486-----224.68-224.680.002.140.00----0.00-91.91-41.01-177.64-48.07------------0.0689------13.71---21.70--
Silexion Therapeutics Corp0.00-523.87k3.65m0.00--0.4022-----0.1403-0.14030.000.65590.00-------3.13---3.77--------------0.00-------54.96------
Revelation Biosciences Inc0.00-15.52m3.65m9.00--1.56-----18.06-18.060.000.62290.00----0.00-148.06---270.02--------------0.00------98.89------
Chromocell Therapeutics Corp0.00-8.98m3.67m4.00--3.24-----1.66-1.660.000.1960.00----0.00-440.01-----------------7.200.00-------200.20------
Matinas BioPharma Holdings Inc0.00-22.91m3.74m32.00--0.1959-----5.10-5.100.003.810.00----0.00-78.48-44.62-85.80-48.25-------2,344.60----0.001---65.6255.71-9.26---16.46--
Artelo Biosciences Inc0.00-10.44m3.78m5.00--0.5174-----3.33-3.330.002.260.00----0.00-82.83---88.23--------------0.00------7.87------
Lixte Biotechnology Holdings Inc0.00-4.03m3.78m3.00---------1.83-1.830.000.99860.00----0.00-139.98-104.18-163.33-111.05-----------563.880.00------19.41------
Data as of Nov 13 2024. Currency figures normalised to NuCana PLC's reporting currency: US Dollar USD
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.